Literature DB >> 33549165

Corticosteroids and mRNA Vaccines: A Word of Caution.

Zifu Zhong1, Francis Combes2, Niek N Sanders3.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33549165      PMCID: PMC7934628          DOI: 10.1016/j.ymthe.2021.01.029

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


× No keyword cloud information.

Main Text

We recently published a paper in Molecular Therapy that studies the impact of corticosteroids and cellulose-based purification on the innate immunity, translation, and efficacy of self-amplifying mRNA (sa-mRNA) vaccines. With this Letter to the Editor, we want to highlight the relevance of a particular subset of data for the ongoing mRNA vaccination campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In our work, we demonstrated in mice that a short course of dexamethasone, hydrocortisone, or clobetasol significantly reduced the type I interferon (IFN) responses and improved the in vivo translation of sa-mRNA vaccines. This is an important observation because it might bring sa-mRNAs for protein (replacement) therapies closer to the clinic. Corticosteroids are also used to suppress immune reactions against Luxturna, an approved adeno-associated virus-based gene therapy for retinal dystrophy. However, for mRNA vaccines, the elicited type I IFN response is considered beneficial because it results in the release of cytokines that shape and promote the adaptive immune responses.2, 3, 4 Nevertheless, a too-strong type I IFN response is known to impede mRNA translation and inhibit the adaptive immune response.5, 6, 7 To maximize the efficacy of mRNA vaccines, it seems that a well-balanced type I IFN response is required. Therefore, we wondered whether this balance could be disturbed when mRNA vaccines were combined with corticosteroids. Surprisingly, a short course of topical clobetasol at the vaccination site completely blunted the humoral (antibody) response elicited by a sa-mRNA vaccine against Zika virus (ZIKVac-sa-mRNA vaccine). In addition, topical hydrocortisone and oral dexamethasone demonstrated a comparable decrease in type I IFN response at the injection site. Therefore, a similar inhibitory effect on the efficacy of mRNA vaccines is expected with oral dexamethasone and topical hydrocortisone. More evidence for the devastating effects of corticosteroids on mRNA vaccines comes from the work of Vormehr et al. These authors found that the number of antigen-specific T cells elicited by an mRNA cancer vaccine was significantly lower if the mice received intraperitoneal dexamethasone 3 h before vaccination. Even more alarming is the observation that their mRNA vaccine started to induce regulatory T cells (Tregs) when combined with dexamethasone. The latter may indicate that immune tolerance is lurking around the corner when mRNA vaccines are given together with certain corticosteroids. In our study, we administered the sa-mRNA vaccine intradermally using electroporation, while Vormehr et al. gave their lipid formulated mRNA vaccine intravenously. Both studies were performed in mice. The current coronavirus disease 2019 (COVID-19) mRNA vaccines are formulated in lipid nanoparticles and given intramuscularly., Despite these differences, it is still very plausible that the vaccination efficacy of the mRNA vaccines against SARS-CoV-2 will also be decreased in patients treated with corticosteroids. Consequently, the immunogenicity and protection efficacy of the SARS-CoV-2 mRNA vaccines in patients who concurrently receive corticosteroids must be urgently investigated. In the meantime, we should consider postponing COVID-19 mRNA vaccination in patients currently receiving high doses of corticosteroids. Corticosteroids induce immunosuppression by interfering with the signaling of nuclear factor κB (NF-κB) and activator protein 1 (AP-1), which results in a decreased expression of pro-inflammatory cytokines and chemokines. Moreover, corticosteroids are widely used for acute and chronic inflammations, including severe allergies, asthma, rheumatoid arthritis, inflammatory bowel diseases, skin diseases, and multiple sclerosis. For example, in the UK, 1% of the total adult population and 2.5% of the elderly between 70 and 79 years of age took oral corticosteroids in the year 2000. Finally, it is possible that other immune suppressive drugs, such as cyclosporine and methotrexate, could also prove detrimental to the vaccination efficacy of mRNA vaccines.
  11 in total

1.  Use of oral corticosteroids in the United Kingdom.

Authors:  T P van Staa; H G Leufkens; L Abenhaim; B Begaud; B Zhang; C Cooper
Journal:  QJM       Date:  2000-02

Review 2.  Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines.

Authors:  Raquel P Deering; Sushma Kommareddy; Jeffrey B Ulmer; Luis A Brito; Andrew J Geall
Journal:  Expert Opin Drug Deliv       Date:  2014-03-26       Impact factor: 6.648

Review 3.  Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response.

Authors:  Sergio Linares-Fernández; Céline Lacroix; Jean-Yves Exposito; Bernard Verrier
Journal:  Trends Mol Med       Date:  2019-11-05       Impact factor: 11.951

4.  Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.

Authors:  Ans De Beuckelaer; Charlotte Pollard; Sandra Van Lint; Kenny Roose; Lien Van Hoecke; Thomas Naessens; Vimal Kumar Udhayakumar; Muriel Smet; Niek Sanders; Stefan Lienenklaus; Xavier Saelens; Siegfried Weiss; Guido Vanham; Johan Grooten; Stefaan De Koker
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

Review 5.  The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.

Authors:  Agnes E Coutinho; Karen E Chapman
Journal:  Mol Cell Endocrinol       Date:  2010-04-14       Impact factor: 4.102

6.  Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine.

Authors:  Zifu Zhong; João Paulo Portela Catani; Séan Mc Cafferty; Liesbeth Couck; Wim Van Den Broeck; Nina Gorlé; Roosmarijn E Vandenbroucke; Bert Devriendt; Sebastian Ulbert; Lieselotte Cnops; Johan Michels; Kevin K Ariën; Niek N Sanders
Journal:  Vaccines (Basel)       Date:  2019-08-23

7.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

8.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.

Authors:  Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks
Journal:  N Engl J Med       Date:  2020-12-30       Impact factor: 91.245

9.  Dexamethasone premedication suppresses vaccine-induced immune responses against cancer.

Authors:  Mathias Vormehr; Sophie Lehar; Lena M Kranz; Siri Tahtinen; Yoko Oei; Vincent Javinal; Lélia Delamarre; Kerstin C Walzer; Mustafa Diken; Sebastian Kreiter; Ira Mellman; Ugur Sahin; Jill M Schartner; Özlem Türeci
Journal:  Oncoimmunology       Date:  2020-05-13       Impact factor: 8.110

View more
  1 in total

Review 1.  Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics.

Authors:  P Vervaeke; S E Borgos; N N Sanders; F Combes
Journal:  Adv Drug Deliv Rev       Date:  2022-03-26       Impact factor: 17.873

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.